{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:03:14Z","timestamp":1782446594649,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007210","name":"RWTH Aachen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007210","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Systemic mastocytosis is a rare genetic disease characterized by aberrant proliferation and\/or activation of mast cells, resulting in multi-organ, allergy-like symptoms. Mast cell activation syndrome (MCAS) is a clinically similar, but more prevalent disease with unclear etiology. In this study, the health-related quality of life (HRQOL) and health literacy of people suffering from SM and MCAS were assessed.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two validated questionnaires (QLQ-C30\/QLQ-INFO25) from the European Organisation for Research and Treatment of Cancer (EORTC) were used to analyze HRQOL and level of information of SM and MCAS patients. In addition, a control group without any health issues was included. Data were analyzed by ANOVA and linear regression to detect significant differences. Questionnaire data from 66 patients with MCAS (83% female, mean 44\u00a0years), 32 patients with SM (78% female, mean 53\u00a0years) and 52 healthy participants (67% female, mean 48\u00a0years) resident in Germany were analyzed. HRQOL as measured by the Global health status was significantly worse in patients suffering from MCAS or SM compared to control group. Individuals with MCAS showed a slightly, but insignificantly lower score on Global health status, and a significantly lower score with respect to role function and fatigue. Patients with the rare disease SM felt significantly better informed on their disease compared to MCAS patients. Linear regression performed separately for both groups showed a direct influence of the level of information on patients' HRQOL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Overall, our study showed a significant negative impact on the HRQOL of both diseases, but only a small difference in quality of life and severity of symptoms between patients with MCAS and the supposedly more severe form, the rare disease SM. Our results demonstrate that the level of information patients receive impacts HRQOL, and that this is not only an issue in rare diseases, but also diseases with unclear etiology and pathology. Our data shows that even slight improvements in the patient's level of information can have a positive effect on their quality of life, further highlighting the importance of gaining more knowledge on rare and incompletely understood diseases and communicating these insights to patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02439-x","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:04:48Z","timestamp":1659092688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Health-related quality of life and health literacy in patients with systemic mastocytosis and mast cell activation syndrome"],"prefix":"10.1186","volume":"17","author":[{"given":"Tobias J\u00fcrgen","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard J.","family":"Molderings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-9035","authenticated-orcid":false,"given":"Martin","family":"M\u00fccke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"issue":"6","key":"2439_CR1","first-page":"849","volume":"20","author":"S Wirz","year":"2017","unstructured":"Wirz S, Molderings GJ. A practical guide for treatment of pain in patients with systemic mast cell activation disease. Pain Phys. 2017;20(6):849\u201361.","journal-title":"Pain Phys"},{"issue":"2","key":"2439_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1515\/dx-2020-0005","volume":"8","author":"LB Afrin","year":"2021","unstructured":"Afrin LB, Ackerley MB, Bluestein LS, Brewer JH, Brook JB, Buchanan AD, et al. Diagnosis of mast cell activation syndrome: a global \u201cconsensus-2.\u201d Diagnosis (Berl). 2021;8(2):137\u201352.","journal-title":"Diagnosis (Berl)"},{"key":"2439_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.trsl.2016.01.001","volume":"174","author":"GJ Molderings","year":"2016","unstructured":"Molderings GJ. Transgenerational transmission of systemic mast cell activation disease\u2014genetic and epigenetic features. Transl Res. 2016;174:86\u201397.","journal-title":"Transl Res"},{"issue":"8","key":"2439_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00063-010-1093-8","volume":"105","author":"J Homann","year":"2010","unstructured":"Homann J, Kolck UW, Ehnes A, Frieling T, Raithel M, Molderings GJ. Die systemische Mastozytose \u2013 Standortbestimmung einer internistischen Erkrankung. Med Klin (Munich). 2010;105(8):544\u201353.","journal-title":"Med Klin (Munich)"},{"key":"2439_CR5","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2009.0174","author":"H-P Horny","year":"2009","unstructured":"Horny H-P, Sotlar K, Valent P, Hartmann K. Mastocytosis\u2014a disease of the hematopoietic stem cell: in reply. Dtsch Arztebl Int. 2009. https:\/\/doi.org\/10.3238\/arztebl.2009.0174.","journal-title":"Dtsch Arztebl Int"},{"key":"2439_CR6","unstructured":"Akin C, Boyce JA. Systemische Mastozytose. In: Harrisons Innere Medizin 3 3. 20th ed. Berlin: Thieme; 2020. p. 3107\u20139."},{"issue":"7","key":"2439_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny H-P, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7):603\u201325.","journal-title":"Leuk Res"},{"issue":"24","key":"2439_CR8","first-page":"A-1744","volume":"102","author":"GJ Molderings","year":"2005","unstructured":"Molderings GJ, Br\u00fcss M, Raithel M, Wilken V, Hartmann K, Brockow K, et al. Systemische Mastozytose als Grund f\u00fcr chronische gastrointestinale Beschwerden: Praxisorientierte Hinweise zu Diagnostik und Therapie. Dtsch Arztebl Int. 2005;102(24):A-1744.","journal-title":"Dtsch Arztebl Int."},{"issue":"2","key":"2439_CR9","doi-asserted-by":"publisher","first-page":"AB275","DOI":"10.1016\/j.jaci.2017.12.875","volume":"141","author":"CR Weiler","year":"2018","unstructured":"Weiler CR, Alhurani RE, Butterfield JH, Divekar R. Systemic mastocytosis (SM) and mast cell activation syndrome (MCAS); how do they differ? J Allergy Clin Immunol. 2018;141(2):AB275.","journal-title":"J Allergy Clin Immunol"},{"issue":"30","key":"2439_CR10","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1055\/s-0034-1370055","volume":"139","author":"G Molderings","year":"2014","unstructured":"Molderings G, Homann J, Brettner S, Raithel M, Frieling T. Systemische Mastzellaktivierungserkrankung: Ein praxisorientierter Leitfaden zu Diagnostik und Therapie. Dtsch med Wochenschr. 2014;139(30):1523\u201338.","journal-title":"Dtsch med Wochenschr"},{"issue":"23","key":"2439_CR11","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.3390\/ijms21239030","volume":"21","author":"P Valent","year":"2020","unstructured":"Valent P, Akin C, Nedoszytko B, Bonadonna P, Hartmann K, Niedoszytko M, et al. Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. IJMS. 2020;21(23):9030.","journal-title":"IJMS"},{"issue":"3","key":"2439_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000328760","volume":"157","author":"P Valent","year":"2012","unstructured":"Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215\u201325.","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"2439_CR13","first-page":"E849","volume":"20","author":"S Wirz","year":"2017","unstructured":"Wirz S, Molderings GJ. A practical guide for treatment of pain in patients with systemic mast cell activation disease. Pain Phys. 2017;20(6):E849\u201361.","journal-title":"Pain Phys"},{"issue":"4","key":"2439_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.anai.2019.12.020","volume":"124","author":"MR Vermeiren","year":"2020","unstructured":"Vermeiren MR, Kranenburg LW, van Daele PLA, Gerth van Wijk R, Hermans MAW. Psychological functioning and quality of life in patients with mastocytosis. Ann Allergy Asthma Immunol. 2020;124(4):373-378.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2439_CR15","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1016\/j.jaip.2021.04.059","volume":"9","author":"S Pulfer","year":"2021","unstructured":"Pulfer S, Ziehfreund S, Gebhard J, Hindelang B, Biedermann T, Brockow K, et al. Health-related quality of life and influencing factors in adults with nonadvanced mastocytosis\u2014a cross-sectional study and qualitative approach. J Allergy Clin Immunol Pract. 2021;9:3166-3175.e2.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"2439_CR16","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/all.12920","volume":"71","author":"B van Anrooij","year":"2016","unstructured":"van Anrooij B, Kluin-Nelemans JC, Safy M, Flokstra-de Blok BMJ, Oude Elberink JNG. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy. 2016;71(11):1585\u201393.","journal-title":"Allergy"},{"issue":"6","key":"2439_CR17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/all.12842","volume":"71","author":"F Siebenhaar","year":"2016","unstructured":"Siebenhaar F, von Tschirnhaus E, Hartmann K, Rabenhorst A, Staubach P, Peveling-Oberhag A, et al. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy. 2016;71(6):869\u201377.","journal-title":"Allergy"},{"issue":"6","key":"2439_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1159\/000356939","volume":"38","author":"M Jhamb","year":"2013","unstructured":"Jhamb M, Liang K, Yabes J, Steel JL, Dew MA, Shah N, et al. Prevalence and correlates of fatigue in chronic kidney disease and end-stage renal disease: are sleep disorders a key to understanding fatigue? Am J Nephrol. 2013;38(6):489\u201395.","journal-title":"Am J Nephrol"},{"issue":"3","key":"2439_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.cnur.2010.03.005","volume":"45","author":"L Hansen","year":"2010","unstructured":"Hansen L, Sasaki A, Zucker B. End-stage liver disease: challenges and practice implications. Nurs Clin N Am. 2010;45(3):411\u201326.","journal-title":"Nurs Clin N Am"},{"issue":"6","key":"2439_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1089\/jpm.2010.0479","volume":"14","author":"DJA Janssen","year":"2011","unstructured":"Janssen DJA, Spruit MA, Uszko-Lencer NH, Schols JMGA, Wouters EFM. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med. 2011;14(6):735\u201343.","journal-title":"J Palliat Med"},{"key":"2439_CR21","doi-asserted-by":"publisher","DOI":"10.21767\/2171-6625.100074","author":"P Batista","year":"2016","unstructured":"Batista P, Pereira A. Quality of life in patients with neurodegenerative diseases. J Neurol Neurosci. 2016. https:\/\/doi.org\/10.21767\/2171-6625.100074.","journal-title":"J Neurol Neurosci"},{"issue":"1","key":"2439_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/0269216307085183","volume":"22","author":"L Radbruch","year":"2008","unstructured":"Radbruch L, Strasser F, Elsner F, Gon\u00e7alves JF, L\u00f8ge J, Kaasa S, et al. Fatigue in palliative care patients\u2014an EAPC approach. Palliat Med. 2008;22(1):13\u201332.","journal-title":"Palliat Med"},{"issue":"6","key":"2439_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/pon.3981","volume":"25","author":"RED Lamers","year":"2016","unstructured":"Lamers RED, Cuypers M, Husson O, Vries M, Kil PJM, Ruud Bosch JLH, et al. Patients are dissatisfied with information provision: perceived information provision and quality of life in prostate cancer patients. Psychooncology. 2016;25(6):633\u201340.","journal-title":"Psychooncology"},{"issue":"4","key":"2439_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/annonc\/mdq413","volume":"22","author":"O Husson","year":"2011","unstructured":"Husson O, Mols F, van de Poll-Franse LV. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2011;22(4):761\u201372.","journal-title":"Ann Oncol"},{"issue":"11","key":"2439_CR25","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1080\/10810730.2015.1018638","volume":"20","author":"JL Halverson","year":"2015","unstructured":"Halverson JL, Martinez-Donate AP, Palta M, Leal T, Lubner S, Walsh MC, et al. Health literacy and health-related quality of life among a population-based sample of cancer patients. J Health Commun. 2015;20(11):1320\u20139.","journal-title":"J Health Commun"},{"issue":"3","key":"2439_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.amjms.2016.12.013","volume":"353","author":"LB Afrin","year":"2017","unstructured":"Afrin LB, Self S, Menk J, Lazarchick J. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353(3):207\u201315.","journal-title":"Am J Med Sci"},{"issue":"9","key":"2439_CR27","doi-asserted-by":"publisher","first-page":"e76241","DOI":"10.1371\/journal.pone.0076241","volume":"8","author":"GJ Molderings","year":"2013","unstructured":"Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, N\u00f6then MM. Familial occurrence of systemic mast cell activation disease. PLoS ONE. 2013;8(9):e76241.","journal-title":"PLoS ONE."},{"key":"2439_CR28","unstructured":"Bauzhadze EV. Ph\u00e4notypische und histologische Charakterisierung von Mastzellaktivit\u00e4tserkrankungen in einem rheumatologischen Patientenkollektiv [Internet]. Universit\u00e4t T\u00fcbingen; 2019 [cited 2021 Mar 21]. https:\/\/publikationen.uni-tuebingen.de\/xmlui\/handle\/10900\/87536."},{"issue":"4","key":"2439_CR29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","volume":"166","author":"SS Cohen","year":"2014","unstructured":"Cohen SS, Skovbo S, Vestergaard H, Kristensen T, M\u00f8ller M, Bindslev-Jensen C, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014;166(4):521\u20138.","journal-title":"Br J Haematol"},{"issue":"23","key":"2439_CR30","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"K-H Lim","year":"2009","unstructured":"Lim K-H, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727\u201336.","journal-title":"Blood"},{"issue":"2","key":"2439_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","volume":"140","author":"C Akin","year":"2017","unstructured":"Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2):349\u201355.","journal-title":"J Allergy Clin Immunol"},{"key":"2439_CR32","first-page":"65","volume":"8","author":"D Magliacane","year":"2014","unstructured":"Magliacane D, Parente R, Triggiani M. Current concepts on diagnosis and treatment of mastocytosis. Transl Med UniSa. 2014;8:65\u201374.","journal-title":"Transl Med UniSa"},{"issue":"8","key":"2439_CR33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/0284186X.2020.1766696","volume":"59","author":"ME Weidema","year":"2020","unstructured":"Weidema ME, Husson O, van der Graaf WTA, Leonard H, de Rooij BH, Hartle DeYoung L, et al. Health-related quality of life and symptom burden of epithelioid hemangioendothelioma patients: a global patient-driven Facebook study in a very rare malignancy. Acta Oncol. 2020;59(8):975\u201382.","journal-title":"Acta Oncol"},{"issue":"1","key":"2439_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00259-017-3816-z","volume":"45","author":"M Marinova","year":"2018","unstructured":"Marinova M, M\u00fccke M, Mahlberg L, Essler M, Cuhls H, Radbruch L, et al. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. Eur J Nucl Med Mol Imaging. 2018;45(1):38\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2439_CR35","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S1701-2163(15)30513-2","volume":"36","author":"FF Teng","year":"2014","unstructured":"Teng FF, Kalloger SE, Brotto L, McAlpine JN. Determinants of quality of life in ovarian cancer survivors: a pilot study. J Obstet Gynaecol Can. 2014;36(8):708\u201315.","journal-title":"J Obstet Gynaecol Can"},{"issue":"4","key":"2439_CR36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/02692163211000628","volume":"35","author":"Mochamat","year":"2021","unstructured":"Mochamat, Cuhls H, Sellin J, Conrad R, Radbruch L, M\u00fccke M. Fatigue in advanced disease associated with palliative care: a systematic review of non-pharmacological treatments. Palliat Med. 2021;35(4):697\u2013709.","journal-title":"Palliat Med."},{"issue":"5","key":"2439_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"15","key":"2439_CR38","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.ejca.2010.06.118","volume":"46","author":"JI Arraras","year":"2010","unstructured":"Arraras JI, Greimel E, Sezer O, Chie W-C, Bergenmar M, Costantini A, et al. An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients. Eur J Cancer. 2010;46(15):2726\u201338.","journal-title":"Eur J Cancer"}],"updated-by":[{"DOI":"10.1186\/s13023-023-02645-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000}}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02439-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T15:05:50Z","timestamp":1676559950000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02439-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2439"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02439-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13023-023-02645-1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"12 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13023-023-02645-1","URL":"https:\/\/doi.org\/10.1186\/s13023-023-02645-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Rheinische Friedrich-Wilhelm-Universit\u00e4t Bonn, Medizinische Fakult\u00e4t, on September 11th, 2018. All patients gave informed, written consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no financial or non-financial competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}